Stock surges 10 per cent after blowout results and $6 bn global licensing deal
20-May-2025•Value Research Team
Adobe Stock
Pfizer just reminded the market it's not done making headlines. Its India arm reported an 85 per cent spike in profit and handed out a Rs 165 dividend. And while investors were still cheering that, the global parent dropped a $6 billion deal on the table, doubling down on cancer drug innovation.
Where should retirees put Rs 20 lakh?
5 min read•By Abhishek Rana
New episodes every Friday
Others' mistakes
The undervalued art of studying investment failures
Other Episodes
It's your life, and your investments
Why trying to invest like the wealthy often backfires spectacularly
Markets defy understanding
Embracing uncertainty might be your best investment strategy
Beyond borders, beyond rules
Investing in foreign stocks is about owning great businesses, not just avoiding domestic market downturns
The vacation test for investments
Something is fundamentally wrong if you can't leave your portfolio alone for a week
5 most-sold small-cap stocks by mutual funds in May 2025
4 min read•By Ujjal Das and Aditya Gupta
Is Waaree Renewables a bargain after the fall?
7 min read•By Kunal Bansal
Widely read:
